Mr. Wenjie Zhang, aged 55, has been the chief executive officer of the Company since September 2020, has been the executive director of the Company since November 2020, and has been the Chairman of the Board since November 2021.
Mr. Zhang served as the senior vice president, chief strategy officer and the chief commercial operation officer of the Company from March 2019 to February 2020, the president of the Company from February 2020 to November 2021. Mr. Zhang has been the president of Shanghai Henlius Biopharmaceutical Co., Ltd. (“Henlius Biopharmaceutical”) since February 2020, director and chief executive officer of Henlius Biopharmaceutical since September 2020, the president of Shanghai Henlius Biologics Co., Ltd. (“Henlius Pharmaceutical”) from February 2020 to March 2021, the chief executive officer of Henlius Pharmaceutical from September 2020 to March 2021 and chairman of the board of directors of Henlius Pharmaceutical since September 2020. Mr. Zhang has been the director of Henlix Biotech Co., Ltd. (“Taiwan Henlius”) since September 2020, the general manager of Taiwan Henlius since December 2020, the director, chief executive director and chief financial officer of Hengenix Biotech, Inc. and the managing director of Henlius Europe GmbH since September 2020. He has been the director of Henlius Industrial Co., Limited since February 2021, the director of Aton (Guangzhou) Biotech Co., Ltd. since November 2021, the director of Shanghai Jollin Tech Co., Ltd. since December 2021, the director of Aton (Shanghai) Biologics Co., Ltd. since January 2022 and the chairman of the board of directors of Aton (Shanghai) Biotech Co., Ltd. since March 2022.
Mr. Zhang has nearly 30 years of commercial operation and management experience in the pharmaceutical industry. Prior to joining the Group, Mr. Zhang previously served in various roles including the general manager at Amgen China, USA, the vice president of oncology business unit 2 of Shanghai Roche Pharmaceuticals, China, and the head of specialty therapeutics & oncology unit-Bayer Schering Pharma, Germany. Mr. Zhang obtained a bachelor’s degree in microbiology from Shandong University (山東大學), the PRC, in July 1990 and a master’s degree of business administration from Yale University, USA, in May 1998.